The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
PARTNER is a prospective, phase II–III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer 1,2, who were germline BRCA1 and BRCA2 wild type 3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin–paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin–paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures











Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For instance, the PARTNER trial reported no added benefit of olaparib when combined with neoadjuvant carboplatin/paclitaxel in BRCA-proficient TNBC, showing no improvement in pCR, event-free survival (EFS), or OS [58].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“For instance, neoadjuvant paclitaxel plus carboplatin achieved a pCR of 52% and a 36-month EFS of 79% in the PARTNER trial (NCT03150576) [58, 59].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 1×
“synthetic lethality by preventing repair of single-strand breaks, which leads to problems downstream with double-strand repair 15,16 .”
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198 · cited 1×
“synthetic lethality by preventing repair of single-strand breaks, which leads to problems downstream with double-strand repair 15,16 .”
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., et al. (2016) · Nature · doi:10.1038/nature17676 · Cited by 2,218
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888 · cited 1×
“The CREATE-X trial demonstrated a significant benefit in patients with TNBC from 6 months of adjuvant capecitabine given after neoadjuvant chemotherapy that left residual disease 25 .”
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729 · cited 1×
“Therefore, after these results, olaparib has been scheduled after completion of chemotherapy, when full and continuous doses are used 8 .”
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Self-citationLehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426 · cited 1×
“Non-basal TNBCs, although triple negative, share few of the biological and genomic features of basal-like TNBC, and respond less well to most systemic treatments 20–22 .”
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112651 · Cited by 1,274
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768 · cited 1×
“Despite this, the delivery of chemotherapy and olaparib was generally more than 90% and rates of pCR were high, comparable with the best from previously reported studies 10 .”
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Molecular Stratification of Triple-Negative Breast Cancers
Perou, C. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-61 · Cited by 582
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547 · cited 1×
“The combination had previously been tested in patients with relapsed ovarian cancer 19 , but the dose and schedule used required reduced doses of carboplatin, and the combination resulted in response rates similar to, rather than superior to, those for carboplatin–paclitaxel alone.”
Tung, N. M., Robson, M. E., Ventz, S., Santa-Maria, C. A., Nanda, R., Marcom, P. K., Shah, P. D., Ballinger, T. J., Yang, E. S., Vinayak, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02151 · Cited by 508 · cited 1×
“24) in a clinically relevant time frame is essential to equip clinicians with the necessary information to apply a precision medicine approach.”
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
(2017) · New England Journal of Medicine · doi:10.1056/nejmx170012 · Cited by 431
Gianni, L., Huang, C. S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.004 · Cited by 396 · cited 1×
“Results from the NeoTRIP trial that tested neoadjuvant ate-zolizumab with chemotherapy 32 showed emerging signals of benefit from immunotherapy in patients with TNBC tumours with evidence of immune activation and remodelling in the tumour microenvironment 33 .”
Spatial predictors of immunotherapy response in triple-negative breast cancer
Wang, X. Q., Danenberg, E., Huang, C.-S., Egle, D., Callari, M., Bermejo, B., Dugo, M., Zamagni, C., Thill, M., Anton, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06498-3 · Cited by 356 · cited 1×
“Results from the NeoTRIP trial that tested neoadjuvant ate-zolizumab with chemotherapy 32 showed emerging signals of benefit from immunotherapy in patients with TNBC tumours with evidence of immune activation and remodelling in the tumour microenvironment 33 .”
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reuterswärd, C., Häkkinen, J., Degasperi, A., Amarante, T. D., Saal, L. H., Hegardt, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0582-4 · Cited by 307
Arora, S., Balasubramaniam, S., Zhang, H., Berman, T., Narayan, P., Suzman, D., Bloomquist, E., Tang, S., Gong, Y., Sridhara, R., et al. (2021) · The Oncologist · doi:10.1002/onco.13551 · Cited by 180 · cited 1×
“In high-grade serous ovarian cancer, widespread adoption of PARP inhibitors in gBRCAwt tumours has already occurred and has been supported by evidence of their activity in those cancers that demonstrate homologous recombination deficiency 17,18 .”
Lluch, A. M., Barrios, C. H., Torrecillas, L., Ruíz‐Borrego, M., Bines, J., Segalla, J. G. M., Zotano, Á. G., García-Sáenz, J. Á., Torres, R., de la Haba-Rodríguez, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00904 · Cited by 160 · cited 1×
“The GEICAM–CIBOMA trial also addressed this question but showed no improvement with capecitabine in patients in the TNBC group as a whole, although it did report benefit in patients in the non-basal TNBC group 26 .”
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.471 · Cited by 146 · cited 1×
“%) in combination with paclitaxel 23 .”
Litton, J. K., Regan, M. M., Pusztai, L., Rugo, H. S., Tolaney, S. M., Garrett-Mayer, E. S., Amiri‐Kordestani, L., Basho, R. K., Best, A. F., Boileau, J.-F., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00435 · Cited by 133
Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F., Wesseling, J., vd Vijver, M. J., de Vries, E. G., van Tinteren, H., Jonkers, J., Hauptmann, M., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3655 · Cited by 110
Shah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1110 · Cited by 105 · cited 1×
“27,28) have resulted in the immune checkpoint inhibitor pembrolizumab becoming licensed for use as neoadjuvant and adjuvant therapy in TNBC by the US Food and Drug Administration 29 , the European Medicines Evaluation Agency 30 and the National Institute for Health and Care Excellence 31 .”
Platinum-based chemotherapy for early triple-negative breast cancer
Mason, S., Willson, M. L., Egger, S. J., Beith, J. M., Dear, R. F.-G., & Goodwin, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014805.pub2 · Cited by 74
Litton, J. K., Beck, J. T., Jones, J. M., Andersen, J., Blum, J. L., Mina, L. A., Brig, R., Danso, M. A., Yuan, Y., Abbattista, A., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad139 · Cited by 55 · cited 2×
“%) in the neoadjuvant setting 22 .”
Sharma, P., Barlow, W. E., Godwin, A. K., Parkes, E. E., Knight, L. A., Walker, S. M., Kennedy, R. D., Harkin, D. P., Logan, G. E., Steele, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00693 · Cited by 53 · cited 5×
“The proportion of patients with pCR was higher for those with tumours with TILs ≥ 60% (65”
InfluentialLi, S., Zhang, Y., Zhang, P., Xue, S., Chen, Y., Sun, L., & Yang, R. (2022) · The Breast · doi:10.1016/j.breast.2022.10.001 · Cited by 46
Schettini, F., Corona, S. P., Giudici, F., Strina, C., Sirico, M., Bernocchi, O., Milani, M., Ziglioli, N., Aguggini, S., Azzini, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.686776 · Cited by 19
Platinum-based chemotherapy for early triple-negative breast cancer
Mason, S., Beith, J. M., Willson, M. L., Egger, S. J., Dear, R. F.-G., & Goodwin, A. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014805 · Cited by 13
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing
Arun, B., Couch, F. J., Abraham, J., Tung, N., & Fasching, P. A. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02827-z · Cited by 94
“…did not improve pCR rates, event-free survival (EFS) or OS compared with paclitaxel and carboplatin alone among patients with non-gBRCAm and TNBC [46], improvements in EFS and OS were observed among patients with gBRCAm who received a gap schedule of olaparib with paclitaxel and carboplatin [45].”
BackgroundMethodSelf-citationHerencia-Ropero, A., Llop‐Guevara, A., Staniszewska, A. D., Domènech-Vivó, J., García‐Galea, E., Moles‐Fernández, A., Pedretti, F., Domènech, H., Rodríguez, O., Guzmán, M., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01370-z · Cited by 90
Triple-Negative Breast Cancer on the Rise: Breakthroughs and Beyond
Agelidis, A. M., Ter‐Zakarian, A., & Jaloudi, M. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s516125 · Cited by 67
Basyuni, S., Heskin, L., Degasperi, A., Black, D., Koh, C. C., Chmelova, L., Rinaldi, G., Bell, S., Grybowicz, L., Elgar, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51577-2 · Cited by 48
Self-citation
Metadata
- Authors
- Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., Worley, J. R., Chhabra, A., Qian, W., Vallier, A.-L., Hardy, R. M., Chan, S., Hickish, T., Tripathi, D., Venkitaraman, R., Persic, M., Aslam, S., Glassman, D., Raj, S., Borley, A., Braybrooke, J. P., Sutherland, S., Staples, E., Scott, L. C., Davies, M., Palmer, C. A., Moody, M., Churn, M. J., Newby, J. C., Mukesh, M. B., Chakrabarti, A., Roylance, R. R., Schouten, P. C., Levitt, N. C., McAdam, K., Armstrong, A. C., Copson, E. R., McMurtry, E., Tischkowitz, M., Provenzano, E., & Earl, H. M.
- Affiliations
- University of Cambridge (GB)
- Athens University of Economics and Business (GR)
- Royal Devon University Healthcare NHS Foundation Trust (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Nottingham University Hospitals NHS Trust (GB)
- Royal Bournemouth Hospital (GB)
- Russells Hall Hospital (GB)
- East Suffolk and North Essex NHS Foundation Trust (GB)
- University Hospitals of Derby and Burton NHS Foundation Trust (GB)
- Bedford Hospital NHS Trust (GB)
- Pinderfields Hospital (GB)
- Royal Hampshire County Hospital (GB)
- Velindre Cancer Centre (GB)
- University Hospitals Bristol and Weston NHS Foundation Trust (GB)
- Mount Vernon Hospital (GB)
- Barking, Havering And Redbridge University Hospitals NHS Trust (GB)
- Beatson West of Scotland Cancer Centre (GB)
- Swansea Bay University Health Board (GB)
- Hinchingbrooke Hospital (GB)
- West Suffolk NHS Foundation Trust (GB)
- Worcestershire Acute Hospitals NHS Trust (GB)
- Royal Free London NHS Foundation Trust (GB)
- Poole Hospital (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- Oxford University Hospitals NHS Trust (GB)
- Peterborough City Hospital (GB)
- The Christie NHS Foundation Trust (GB)
- University of Southampton (GB)
- Corresponding author
- Abraham, Jean E.
- ORCID
- Abraham, Jean E.
- Pinilla, Karen
- Dayimu, Alimu
- Grybowicz, Louise
- Lucey, Rebecca
- Fulton, Alexander
- Chhabra, Anita
- Qian, Wendi
- Hickish, Tamas
- Tripathi, Devashish
- Venkitaraman, Ramachandran
- Borley, Annabel
- Braybrooke, Jeremy P.
- Churn, Mark J.
- Chakrabarti, Amitabha
- Roylance, Rebecca R.
- Schouten, Philip C.
- McAdam, Karen
- Armstrong, Anne C.
- Copson, Ellen R.
- Tischkowitz, Marc
- Provenzano, Elena
- Earl, Helena M.
- Venue
- Nature
- Published
- 2024-04-08
- Volume
- 629
- Issue
- 8014
- Pages
- 1142-1148
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC11136660
- OpenAlex
- W4394580299
- Cited by
- 53
- References
- 36
- Citations by year
- 2026: 20 · 2025: 22 · 2024: 11
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, triple-negative breast cancer, neoadjuvant therapy, PARP inhibitors, carboplatin, paclitaxel, anthracycline chemotherapy, pathological complete response, event-free survival, overall survival
- MeSH terms
- Progression-Free Survival, Pathologic Complete Response, Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Middle Aged, Phthalazines, Piperazines, Prospective Studies, Time Factors, Survival Analysis, Carboplatin, Paclitaxel, Germ-Line Mutation, Anthracyclines, BRCA1 Protein, Genes, BRCA1, Neoadjuvant Therapy, Genes, BRCA2, BRCA2 Protein, Young Adult, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.